Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK plus NSCLC
JOURNAL OF THORACIC ONCOLOGY（2021）
关键词
ALK plus NSCLC, crizotinib, Alectinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要